Lord, Abbett & Co
PRAX icon

Lord, Abbett & Co’s Praxis Precision Medicines PRAX Stock Holding History

Lord, Abbett & Co’s Portfolio PRAX Stock Details PRAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.93M Buy
29,662
+43
+0.1% +$13.6K 0.03% 388
2026
Q1 		$9.54M Sell
29,619
-1,137
-4% -$352K 0.03% 369
2025
Q4 		$9.06M Buy
+30,756
New +$5.73M 0.03% 392

Other funds holding PRAX

JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Lord, Abbett & Co's PRAX Position: Q2 2026 in Review

Lord, Abbett & Co increased its Praxis Precision Medicines (PRAX) stake by 0.15% in Q2 2026, buying an estimated $13.6K and bringing the position to 29,662 shares worth $9.93M. The position accounts for 0.03% of the portfolio, ranked #388.

Lord, Abbett & Co first reported a position in PRAX in Q4 2025 and has held it in 3 quarters since. 310 funds tracked by Wall St. Rank hold PRAX as of Q2 2026.

  • Lord, Abbett & Co held 29,662 shares of Praxis Precision Medicines worth $9.93M as of Q2 2026.
  • Lord, Abbett & Co bought 43 Praxis Precision Medicines shares in Q2 2026, an estimated $13.6K.
  • Praxis Precision Medicines made up 0.03% of Lord, Abbett & Co's portfolio in Q2 2026, its #388 holding.
  • Lord, Abbett & Co first reported a position in Praxis Precision Medicines in Q4 2025 and has held it in 3 quarters since.
  • 310 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q2 2026.

Based on Lord, Abbett & Co's 13F filing for Q2 2026, filed 14 Aug 2026.